Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1881-1900 of 2,120 trials

Lung Cancer: RMC-6236 vs. Docetaxel

We are studying a new treatment for patients with advanced lung cancer who have RAS mutations. The goal is to see if RMC-6236 works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

HER2-Positive Breast Cancer: New Treatment Without Chemotherapy

We are studying a combination of trastuzumab, pertuzumab, and tucatinib for patients with stage II-III HER2-positive breast cancer. The goal is to evaluate the safety and initial effectiveness of this chemotherapy-free approach.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Heart Attack Treatment: Evolocumab vs. Standard Care

We are studying whether the medication evolocumab can better prevent heart-related problems compared to standard treatments for patients who have recently had a heart attack. This trial focuses on improving cholesterol control and reducing hospitalizations.

Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Pancreatic Cancer: Napabucasin with Chemotherapy

We are studying how well Napabucasin works with chemotherapy for patients with metastatic pancreatic cancer after previous treatments have failed. The goal is to see if this combination improves survival and quality of life compared to standard care.

Metastatic Pancreatic CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Plozasiran for Severe Hypertriglyceridemia: SHASTA-5 Study

We are studying whether plozasiran can help adults with severe hypertriglyceridemia reduce their triglyceride levels and lower the risk of acute pancreatitis. The trial also looks at the treatment's safety and how it affects patients' overall health.

High Triglycerides>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

Hereditary Angioedema: BW-20805 Study

We are investigating the effects and safety of BW-20805 in adults with hereditary angioedema. The study aims to see if it can help reduce the number of HAE attacks.

Hereditary Angioedema1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInternal Medicine

Ketamine Therapy for Obsessive-Compulsive Disorder

We are studying whether ketamine can effectively reduce symptoms of obsessive-compulsive disorder. This trial will help us understand its impact on mental function during stressful situations.

Obsessive Compulsive Disorder (OCD)≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

Growth Hormone and Liver Fat Metabolism Study

We are investigating how growth hormone influences fat processing in the liver of healthy adults. Additionally, we will explore its effects in patients with acromegaly to understand fat secretion better.

AcromegalyHealthy Participants≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyHepatology

Metastatic Non-Small-Cell Lung Cancer: Tedopi Combinations

We are studying the effects of Tedopi combined with either docetaxel or nivolumab in patients with advanced lung cancer who have not responded to previous treatments. This trial aims to see if these combinations can improve survival rates and overall health.

Metastatic Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Fecal Incontinence: ICEF15 Therapy

We are testing a new treatment for fecal incontinence caused by anal sphincter weakness. The study aims to see if this therapy improves symptoms and enhances quality of life for patients.

Fecal Incontinence1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterology

Acute Myeloid Leukemia: NOPHO-DBH AML 2012 Study

We are researching new treatment options for children and adolescents with acute myeloid leukemia. The goal is to find more effective therapies while reducing side effects and improving overall outcomes.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyPediatrics

Psychiatric Disorders: Immunotherapy Study

We are testing whether immunotherapy can help patients with psychotic symptoms and autoimmune conditions when added to their ongoing psychiatric care. This study aims to improve understanding of treatment options for these patients.

Mental Disorder1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPsychiatry

Primary Plasma Cell Leukemia: New Treatment with Bortezomib and Daratumumab

We are studying a combination of medications for people with primary plasma cell leukemia to see if it improves treatment outcomes and safety. This trial will help us understand how well this new approach works compared to current treatments.

Plasma Cell Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Lung Cancer: JNJ-90301900 with Chemoradiation

We are studying a new drug combined with standard treatments for patients with advanced non-small cell lung cancer. The goal is to see if this combination improves treatment response.

Locally Advanced Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Type 2B von Willebrand Disease: BT200 Treatment Study

We are testing a new treatment called BT200 for people with Type 2B von Willebrand disease. The goal is to see if it improves blood clotting and is safe for use.

Von Willebrand's Disease Type 2B≤3 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesHematology

Crohn’s Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn’s disease. The goal is to see if it helps achieve remission and improve symptoms compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Uncontrolled Asthma: GSK5784283 Treatment Study

We are testing a new antibody treatment for adults with uncontrolled asthma to see if it helps improve lung function and asthma control compared to a placebo.

Asthma1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonology

Advanced GEP-NET: [177Lu]Lu-DOTA-TATE Treatment Study

We are testing a new treatment combining [177Lu]Lu-DOTA-TATE and octreotide LAR for patients with advanced Grade 1 and Grade 2 GEP-NET. The goal is to see if it can better delay disease progression and improve quality of life compared to existing therapies.

Gastroenteropancreatic Neuroendocrine Tumors1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Idiopathic Pulmonary Fibrosis: CAL101 Treatment Study

We are studying whether CAL101 can improve lung function in patients with idiopathic pulmonary fibrosis compared to a placebo. The trial also looks at the safety of this new treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Transthyretin Amyloidosis with Cardiomyopathy: Vutrisiran Study

We are evaluating the safety and effectiveness of vutrisiran in patients with transthyretin amyloidosis and heart issues. This study includes those continuing treatment or switching from another medication.

Cardiac Amyloidosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine